Werewolf Therapeutics, Inc. (HOWL)

Market Cap	39.04M
Revenue (ttm)	1.14M
Net Income (ttm)	-72.41M
Shares Out	44.87M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,423
Open	0.9210
Previous Close	0.9210
Day's Range	0.8600 - 0.9210
52-Week Range	0.5950 - 6.3400
Beta	0.49
Analysts	Strong Buy
Price Target	9.00 (+934.48%)
Earnings Date	May 8, 2025

About HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. The company’s lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: HOWL
• Website: https://werewolftx.com

Financial Performance

In 2024, Werewolf Therapeutics's revenue was $1.89 million, a decrease of -90.55% compared to the previous year's $19.94 million. Losses were -$70.52 million, 88.7% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for HOWL stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 934.48% from the latest price.

Price Target

$9.0

(934.48% upside)

Analyst Consensus: Strong Buy